<?xml version="1.0" encoding="UTF-8"?>        <feed xmlns="http://www.w3.org/2005/Atom">
            <title type="text">Latest imported feed items on SAEDYN</title>
                        <entry>
                <title><![CDATA[What Would Show That Strength Is Preserved During Semaglutide Weight Loss?]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71570?af=R" />
                <published>2026-11-17T03:59:31Z</published>
                <content type="html"><![CDATA[<p>Diabetes, Obesity and Metabolism, EarlyView. </p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Real‐World Initiation of Resmetirom and Recorded Incretin Exposure in the United States]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71562?af=R" />
                <published>2026-11-17T03:58:35Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Aims</h2>
<p>Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction-associated steatohepatitis but have not been tested together. We examined recorded incretin exposure among resmetirom initiators and the frequency and correlates of co-initiation.</p>
<h2>Materials and Methods</h2>
<p>This new-user cohort study used TriNetX US Collaborative Network health records of patients first prescribed resmetirom from 14 March 2024 to 16 July 2026. Among patients without incretin prescriptions in the prior 5 years, those with an incretin prescription 0–30 days after resmetirom (co-initiators) were compared with non-co-initiators using standardized mean differences (SMDs) and Mantel–Haenszel analysis stratified by overweight/obesity and Type 2 diabetes.</p>
<h2>Results</h2>
<p>Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m<sup>2</sup>), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co-initiators. Coded overweight/obesity (49.4% vs. 49.0%; SMD: 0.01) and Type 2 diabetes (30.3% vs. 33.1%; SMD: 0.06) were similar; co-initiation was about 5% in every stratum (Mantel–Haenszel odds ratios: overweight/obesity 1.08 [95% CI: 0.80–1.46]; diabetes 1.00 [0.75–1.34]). Co-initiators had higher mean BMI (35.3 vs. 33.0 kg/m<sup>2</sup>; SMD: 0.33) and were more often prescribed metformin (27.7% vs. 19.0%; SMD: 0.21).</p>
<h2>Conclusions</h2>
<p>Because more than one-third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed. Co-initiation was uncommon and not clearly associated with overweight/obesity or Type 2 diabetes, despite higher BMI in co-initiators.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin‐Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta‐Analysis]]></title>
                <link href="https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70252?af=R" />
                <published>2026-11-17T02:54:33Z</published>
                <content type="html"><![CDATA[<p><img decoding="async" src="https://onlinelibrary.wiley.com/cms/asset/8c1b267f-95c6-49d6-95eb-3fa595d83989/dmrr70252-toc-0001-m.png" alt="Comparative Efficacy and Safety of Different Triple Oral Antidiabetic Therapy Regimens and Insulin-Based Therapy Regimens Following Dual Therapy Failure in Type 2 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis" /></p>
<p></p>
<h2>ABSTRACT</h2>
<h2>Aims</h2>
<p>The aim of this systematic review and network meta-analysis was to compare the efficacy and safety of triple oral antidiabetic therapy (3OADs) and insulin-based therapy in patients with type 2 diabetes after dual therapy failure.</p>
<h2>Materials and Methods</h2>
<p>Medline (PubMed), Embase, Web of Science, and Cochrane Library were systematically searched (from inception to September 1, 2023). The network meta-analysis included randomized clinical trials (RCTs) of 3OADs and/or insulin-based therapies after dual therapy failure. Mean difference (MD) was extracted for changes in HbA1c and body weight; odds ratio (OR) was extracted for hypoglycemia and adverse events.</p>
<h2>Results</h2>
<p>Forty-two articles (13,911 adult patients) were analysed. 3OADs versus insulin-based therapy showed comparable HbA1c reduction (MD 0.01%; 95% CI, −0.56 to 0.58), weight change (MD -1.59 kg; 95% CI, −3.67 to 0.48), hypoglycemia (OR 0.70; 95% CI, 0.37–1.30), and adverse events (OR 1.68; 95% CI, 1.00–2.82) at 22–36 weeks. Sensitivity analysis revealed that 3OADs significantly reduced weight compared with insulin-based therapy (MD −3.30 kg; 95% CI, −5.56 to −1.05). No significant differences in HbA1c reduction, hypoglycemia incidence, or adverse events were observed between metformin (Met) + dipeptidyl peptidase-4 inhibitor (DPP-4i) + sodium-glucose cotransporter-2 inhibitor (SGLT-2i) and other 3OAD regimens. Meanwhile, Met + DPP-4i + SGLT-2i had the highest probability of achieving the greatest weight reduction.</p>
<h2>Conclusions</h2>
<p>Compared with insulin-based therapy, 3OADs demonstrated comparable glucose-lowering effects and safety profiles, with a significant weight-sparing benefit observed in sensitivity analysis. Among all 3OAD combinations, Met + DPP-4i + SGLT-2i ranked first for weight loss, without increasing hypoglycemia risk.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Impact of Different Meal Types and Macronutrients on Circulating FGF21 and Appetite in Humans: A Systematic Review of Randomized Trials]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71457?af=R" />
                <published>2026-11-17T01:35:45Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Introduction and Aim</h2>
<p>Fibroblast growth factor 21 (FGF21) is potentially involved in macronutrient specific appetite regulation by increasing preference for protein and suppressing preference for sugar and alcohol. The aim of this systematic review was to investigate how different macronutrients, including carbohydrates and specific sugars, protein, fat, alcohol and non-sugar sweeteners, impact circulating FGF21 in humans and how food preference or appetite is associated with circulating FGF21 in response to a dietary intervention.</p>
<h2>Methods</h2>
<p>A systematic search was conducted in the databases MEDLINE, EMBASE and CENTRAL on 9 December 2025. Eligible for inclusion were randomized controlled dietary or meal intervention studies in healthy adults, where circulating FGF21 had been measured in response to the intervention.</p>
<h2>Results</h2>
<p>A total of 4163 records were identified, resulting in 24 included articles. Sugar, especially fructose, but also alcohol, increased postprandial FGF21 concentrations acutely, whereas protein suppressed them. Interventions lasting ≥ 24 h showed an increase in fasting FGF21 concentrations after low protein intake. No studies on non-sugar sweeteners were identified. Studies investigating appetite and food preferences following diet-induced FGF21 changes were very limited and inconsistent.</p>
<h2>Conclusion</h2>
<p>FGF21 responds to changes in macronutrient compositions in humans. Specifically, fructose and alcohol increased FGF21, while protein suppressed FGF21. Evidence linking FGF21 to appetite or food preferences or non-sugar sweeteners was limited in humans.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Use of artificial intelligence in evidence synthesis for EASD guidelines: an EASD Guidelines Oversight Committee statement]]></title>
                <link href="https://link.springer.com/article/10.1007/s00125-026-06912-1" />
                <published>2026-11-17T00:00:00Z</published>
                <content type="html"><![CDATA[<p>              Graphical Abstract</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Association of Continuous Glucose Monitoring‐Based Nocturnal Glucose Patterns With Microvascular Complications in Patients With Type 2 Diabetes]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71560?af=R" />
                <published>2026-11-16T08:29:33Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Aims</h2>
<p>To characterize metabolic heterogeneity in Type 2 diabetes mellitus (T2DM), we used continuous glucose monitoring (CGM) data to identify nocturnal glucose patterns and examine their associations with clinical and metabolic characteristics and microvascular complications.</p>
<h2>Materials and Methods</h2>
<p>This cross-sectional study analysed CGM data from 3218 patients with T2DM at a single centre (training set, <i>n</i> = 2214; validation set, <i>n</i> = 1004). We first identified nocturnal glucose patterns using k-means clustering based on glucose dynamic features (GDF). After excluding subtypes dominated by high or low glucose levels, we baseline-corrected the remaining nocturnal glucose curves, extracted morphological features and repeated clustering. We then compared clinical characteristics and the prevalence of diabetic retinopathy (DR) and diabetic kidney disease (DKD) across subtypes, and evaluated reproducibility in the validation set.</p>
<h2>Results</h2>
<p>GDF-based clustering identified five nocturnal glucose patterns that differed in CGM metrics, β-cell function and insulin resistance indices (all <i>p</i> &lt; 0.001). Baseline-corrected clustering identified stable, declining and rising relative trajectories. Compared with stable trajectories, rising trajectories were associated with prevalent DR (OR = 1.38, 95% CI: 1.04–1.82), and declining trajectories with prevalent DKD (OR = 1.28, 95% CI: 1.00–1.63) in adjusted models for the training set. These associations were reproduced in temporal internal validation, and corresponding adjusted prevalence-ratio associations remained significant after false discovery rate correction.</p>
<h2>Conclusions</h2>
<p>Nocturnal glucose patterns characterize heterogeneity in metabolic profiles and prevalent microvascular complications in T2DM. Longitudinal studies are needed to clarify the temporal direction of these associations.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Endoscopic Ultrasound‐Guided Bypass Reversal for Postprandial Reactive Hypoglycaemia After Roux‐En‐Y Gastric Bypass Surgery: Results of a Prospective Pilot Study]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71548?af=R" />
                <published>2026-11-16T08:27:21Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Background and Aim</h2>
<p>Postprandial reactive hypoglycaemia syndrome (PRHS) is an increasingly recognized complication after Roux-en-Y gastric bypass (RYGB) surgery. We investigated whether endoscopic ultrasound (EUS)-guided bypass reversal could provide a minimally invasive alternative to surgery in patients with severe, therapy-refractory PRHS.</p>
<h2>Methods</h2>
<p>We conducted a prospective pilot study in 12 patients with severe, therapy-refractory PRHS after RYGB. A 20 × 10 mm lumen-apposing metal stent (LAMS) was placed between the gastric pouch and excluded stomach. Patients were followed for 6 months with four visits and a mixed-meal test at 6 months. Primary outcomes were immediate and sustained clinical response. Secondary outcomes included technical success, quality of life assessed using a visual analogue scale (VAS), adverse events and weight change.</p>
<h2>Results</h2>
<p>Technical success was achieved in all patients. Immediate clinical response occurred in 10/12 patients (83.3%). Sustained response was observed in 7/10 patients with 6-month follow-up (70.0%; 7/8 responders). At 6 months, median VAS increased by 5.0 points (97.85% CI: 0.0–8.0) in all patients and by 6.0 points (99.22% CI: 2.0–8.0) in responders. Adverse events occurred in 2/10 patients and were moderate. One patient developed gastric discomfort and reflux; another experienced stent migration with loss of response, restored after endoscopic repositioning and fixation. Mean weight change at 6 months was −0.3 kg (95% CI: −3.89 to 3.29).</p>
<h2>Conclusion</h2>
<p>In this prospective pilot study, EUS-guided gastric bypass reversal was feasible, appeared safe and was associated with a promising clinical response in severe, therapy-refractory PRHS after RYGB. Larger studies are needed to confirm these preliminary findings.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[GLP‐1(9‐37) Improves Left Ventricular Function in a Murine Model of Cardiac Pressure Overload by Promoting Mitochondrial Biogenesis]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71541?af=R" />
                <published>2026-11-16T08:21:11Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Aim</h2>
<p>Glucagon-like peptide-1 (GLP-1) is an incretin hormone that is released in response to nutrient intake and inflammation. Its active form, GLP-1(7-37), binds to the GLP-1 receptor (GLP-1R), but GLP-1 is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) into GLP-1(9-37), which does not bind to the classical GLP-1R. Both peptides exhibit cardioprotective effects, although the underlying mechanisms are unclear and the role of GLP-1(9-37) remains poorly understood.</p>
<h2>Methods and Results</h2>
<p>In this study, we investigated cardiac and metabolic effects of GLP-1(9-37) in a mouse model of cardiac pressure overload. LacZ and GLP-1(9-37) were overexpressed using an AAV vector system. While GLP-1(9-37) does not affect glucose metabolism, it mechanistically activates key metabolic regulators, as evidenced by increased AMPK and PGC1α signalling. This shift suggests an improvement in cellular energy balance and mitochondrial function under hypertrophic stress conditions. GLP-1(9-37) was also found to mitigate adverse cardiac remodelling. Treatment is associated with reduced septal thickness and decreased cardiac fibrosis, indicating attenuation of structural hypertrophy.</p>
<h2>Conclusions</h2>
<p>In summary, our data suggest a protective role of GLP-1(9-37) in pressure-overload-induced cardiac remodelling, which is associated with AMPK/PGC1α-signalling.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Comparison of Sensor Accuracy for Three Different CGM‐Systems Using Either Displayed or Auto‐Logged Values in Individuals With Type 1 Diabetes Mellitus]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71537?af=R" />
                <published>2026-11-16T08:18:16Z</published>
                <content type="html"><![CDATA[<p>Diabetes, Obesity and Metabolism, EarlyView. </p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 10 mg in Korean Adults With Type 2 Diabetes: A Multicentre, Randomised, Double‐Blind, Placebo‐Controlled Phase III Trial]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71501?af=R" />
                <published>2026-11-16T08:17:31Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Aims</h2>
<p>To evaluate the efficacy and safety of anagliptin added to metformin and empagliflozin 10 mg in adults with Type 2 diabetes (T2D) with inadequate glycaemic control.</p>
<h2>Materials and Methods</h2>
<p>In this multicentre, randomised, double-blind, placebo-controlled Phase III trial, participants receiving metformin (≥ 1000 mg/day) plus empagliflozin 10 mg/day were randomised 1:1 to anagliptin 100 mg twice daily or placebo for 24 weeks. The primary endpoint was change in glycated haemoglobin (HbA1c) at Week 24 in the full analysis set, analysed using a mixed-effects model for repeated measures. Secondary endpoints included fasting plasma glucose (FPG), HbA1c target attainment, HOMA-β and safety. Glycaemic responder analyses were conducted post hoc.</p>
<h2>Results</h2>
<p>The full analysis set included 195 participants (anagliptin, <i>n</i> = 97; placebo, <i>n</i> = 98). At Week 24, LS mean HbA1c changes were −0.81% and −0.24%, respectively, yielding a treatment difference of −0.57% (95% CI −0.74 to −0.40; <i>p</i> &lt; 0.0001). FPG was also significantly reduced (between-group difference −12.15 mg/dL, 95% CI −19.18 to −5.12; <i>p</i> = 0.0008). HbA1c ≤ 7.0% was achieved by 55.7% versus 25.5% of participants. HbA1c reductions ≥ 0.5% occurred in 68.0% versus 27.6%, and reductions ≥ 1.0% in 33.0% versus 9.2%. HOMA-β improved significantly with anagliptin (between-group difference 14.35, 95% CI 7.37–21.32; <i>p</i> &lt; 0.0001). Treatment-emergent adverse events occurred in 22.7% and 17.2%, respectively; no hypoglycaemic events or deaths were reported.</p>
<h2>Conclusions</h2>
<p>Anagliptin added to metformin and empagliflozin 10 mg provided confirmatory evidence of additional glycaemic efficacy in a separately randomised Korean population, increased glycaemic responder rates and improved estimated β-cell function, with acceptable short-term tolerability.</p>
<h2>Trial Registration</h2>
<p><a target="_blank" title="Link to external resource" href="http://clinicaltrials.gov">ClinicalTrials.gov</a> identifier: NCT05814406</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[MCP‐1 as a Biomarker of Vascular Function]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71544?af=R" />
                <published>2026-11-16T08:15:12Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Background</h2>
<p>Endothelial dysfunction and arterial stiffness have been shown to be associated with cardiovascular disease (CVD) outcomes but assessment of these is not straightforward. CVD risk in diabetes shows heterogeneity and new biomarkers are required to stratify CVD risk in these patients. The aim of this study was to determine the association between MCP-1 and measures of endothelial function and large artery stiffness, independently of traditional CVD risk factors, in patients with and without Type 2 diabetes mellitus (T2DM).</p>
<h2>Methods</h2>
<p>This study analysed the association of monocyte chemoattractant protein-1 (MCP-1) with measures of vascular function in 477 patients with T2DM and 261 patients without T2DM. Endothelium-dependent and endothelium-independent microvascular responses were assessed by measuring vasodilator responses to iontophoresis of acetylcholine (ACh) and sodium nitroprusside (SNP), respectively, using laser Doppler imaging (LDI). Large artery stiffness was measured using carotid-femoral pulse wave velocity (cf-PWV).</p>
<h2>Results</h2>
<p>MCP-1 was inversely associated with ACh and SNP responses, in patients with and without T2DM. Each SD higher MCP-1 was associated with lower ACh (<i>β</i> = −21.7 AU, 95% CI: −34.3 to −9.0) and SNP (<i>β</i> = −20.5 AU, 95% CI: −32.5 to −8.4) responses after adjustment for CVD risk factors, BMI, HbA1c, eGFR, medication and study centre, with similar associations in patients with and without T2DM. MCP-1 was not associated with the ACh:SNP ratio or with cf-PWV, and the associations were not modified by BMI.</p>
<h2>Conclusion</h2>
<p>This study shows MCP-1 to be associated with reduced microvascular vasodilator capacity, affecting endothelium-dependent and endothelium-independent responses, in patients with and without T2DM, independently of adiposity. Longitudinal studies in larger cohorts are required to determine whether MCP-1 improves CVD risk prediction and identifies patients most likely to benefit from targeted therapy.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Urinary Metabolic and Hemodynamic Protein Signatures in Canagliflozin Treated Patients With Diabetic Kidney Disease: Findings From CREDENCE]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71518?af=R" />
                <published>2026-11-16T04:09:11Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Background</h2>
<p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) provide kidney protection in patients with diabetic kidney disease (DKD). There is limited knowledge about the mechanisms by which they protect the kidney. We investigated which urinary proteins and pathways are associated with progressive kidney disease and canagliflozin treatment.</p>
<h2>Materials and Methods</h2>
<p>This case–control study included patients from the CREDENCE trial. Cases and controls were defined by annual eGFR decline of ≥ 5 or &lt; 1 mL/min/1.73 m<sup>2</sup> and propensity score-matched within treatment arms. High-throughput urinary proteomics (SomaLogic, <i>n</i> = 5284 aptamers) was performed at baseline and year 1. Differential abundance analysis assessed 1-year changes between cases and controls, and between canagliflozin and placebo-treated patients. Identified proteins were mapped to kidney biopsy single-cell RNA sequencing (scRNA-seq) data from patients with type 2 diabetes, with or without SGLT2i treatment to identify cell type-specific expression.</p>
<h2>Results</h2>
<p>Of 392 included participants, 250 were randomized to canagliflozin and 142 to placebo. After 1 year, 124 proteins were changed by canagliflozin compared to placebo (92 increased and 32 decreased). Enolase 1, SLIT, NTRK Like Family Member 1, and leucine-rich repeat containing 15 increased more than 3-fold, while decreases were observed in alanyl aminopeptidase, discoidin domain receptor 1 and ameloblastin. Pathway analysis revealed enhanced activity of metabolic pathways. scRNA-seq data showed increased expression of metabolic genes after SGLT2i treatment in distal tubular cells.</p>
<h2>Conclusion</h2>
<p>These findings suggest that SGLT2i administration induces a redistribution of tubular workload through compensatory sodium reabsorption in distal parts of the nephron, which may contribute to kidney-protective effects in DKD.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[A Cost‐Effectiveness Analysis of FreeStyle Libre Real‐Time Continuous Glucose Monitoring System Compared With Self‐Monitoring of Blood Glucose in Adults With Type 2 Diabetes on Basal Insulin Plus SGLT2 Inhibitor and/or GLP‐1 Agonists in the United Kingdom]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71476?af=R" />
                <published>2026-11-16T04:06:55Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Aims</h2>
<p>We previously showed that FreeStyle Libre (FSL) real-time continuous glucose monitoring system (rtCGM) reduces glycated haemoglobin (HbA1c) at 16 and 32 weeks compared with capillary self-monitoring of blood glucose (SMBG) in adults with Type 2 diabetes and above target glucose levels, managed with basal insulin and SGLT-2 inhibitor and/or GLP-1 agonist therapy. We assess the cost-effectiveness of rtCGM compared with SMBG.</p>
<h2>Materials and Methods</h2>
<p>Participant-level baseline and follow-up health status (Euroqol-5-dimensions-5-levels) and within-trial healthcare resource-use data were collected. We estimated quality-adjusted life-years (QALYs) and participant-level costs at 16 and 32 weeks. Long-term cost-effectiveness from the United Kingdom National Health Service perspective was evaluated using the IQVIA CORE Diabetes Model with a 3.5% discount rate. Sensitivity analyses assessed structural and parameter uncertainty.</p>
<h2>Results</h2>
<p>Within-trial analyses found no significant difference at 32 weeks between rtCGM and SMBG in QALYs or healthcare costs. At 32 weeks, adjusted incremental QALYs were −0.015 (95% CI: −0.031 to 0.003) and incremental costs were £254 (95% CI: −£587 to £1070). The lifetime projected incremental QALYs were 0.730 (95% CI: 0.688–0.773) and incremental costs were £4341 (95% CI: 3558–5125), generating an incremental cost-effectiveness ratio (ICER) of £5943 per QALY. At least 4 years of maintained glycaemic benefits are required for rtCGM to be cost-effective. Sensitivity analyses were robust to the base-case results.</p>
<h2>Conclusions</h2>
<p>Benefits of FSL rtCGM in lowering HbA1c in people with Type 2 diabetes on basal insulin plus SGLT-2 inhibitor and/or GLP-1 agonist therapy is likely to justify costs through improved health outcomes and reduced long-term costs of diabetes-related complications.</p>
]]></content>
            </entry>
                        <entry>
                <title><![CDATA[Pre‐Treatment Biomarkers Associated With Remission of Type 2 Diabetes in Response to Short‐Term Insulin‐Based Therapy]]></title>
                <link href="https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71551?af=R" />
                <published>2026-11-16T04:05:10Z</published>
                <content type="html"><![CDATA[<h2>ABSTRACT</h2>
<h2>Aims</h2>
<p>Short-term insulin-based therapy can induce remission of Type 2 diabetes (T2DM) in some but not all patients. The underlying determinant of whether remission can be achieved is beta-cell function, but its assessment typically requires complex challenge testing. We thus sought to determine if there exist circulating biomarkers associated with the likelihood of achieving remission prior to initiating short-term insulin-based therapy, without requiring challenge testing.</p>
<h2>Methods</h2>
<p>Adults with T2DM of ≤ 7 years duration were randomized to 8 weeks treatment with (i) insulin glargine, (ii) glargine + thrice-daily lispro or (iii) glargine + twice-daily exenatide, followed by 12 weeks washout that enabled assessment for remission (A1c &lt; 6.5% after ≥ 3 months without glucose-lowering therapy). We assessed the following fasting biomarkers at baseline in relation to subsequent remission: fibroblast growth factor-21 (FGF-21), C-reactive protein (CRP), vascular cell adhesion molecule-1 (VCAM-1), interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-4 (IL-4), monocyte chemoattractant protein-1 (MCP-1) and dipeptidyl peptidase-4 (DPP-4).</p>
<h2>Results</h2>
<p>Remission occurred in 31 of 90 participants (34.4%). At baseline, compared to their non-remitting peers, those in whom remission was subsequently achieved had higher Homeostasis Model Assessment of beta-cell function (HOMA-B; <i>p</i> = 0.02), lower fasting proinsulin: C-peptide ratio (<i>p</i> = 0.008) and borderline higher prevalence of detectable IL-4 (<i>p</i> = 0.06), though significance did not persist after multiplicity-adjustment. On exploratory logistic regression analyses, baseline detectable IL-4 (aOR = 3.58; 95% CI: 1.25–10.99) and HOMA-B (aOR = 1.77; 95% CI: 1.11–2.99) were associated with remission.</p>
<h2>Conclusion</h2>
<p>Prior to treatment, higher HOMA-B and detectable IL-4 are candidate markers warranting further study for association with subsequent remission of T2DM in response to short-term insulin-based therapy.</p>
]]></content>
            </entry>
                    </feed>
        